Ocuphire Pharma Investor Day Presentation Deck
P
86
VEGA-1: Photopic and Mesopic Distance Vision Effects
Nyxol and/or LDP Demonstrated No Loss of Distance Vision in Photopic and Mesopic Lighting
Percent of Subjects (%)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Percent of Subjects With Improvement or Loss From
Baseline in Photopic BCDVA at 1 hour
9%
28%
20% 19%
91%
72%
77%
74%
VEGA-1 Phase 2 Trial
Greater than or Equal to 5
Letter Gain
Placebo (n=43) Nyxol+LDP (n=43) ■Nyxol (n=30)
Within 5 Letters
No Loss of Distance
Vision
0% 0%
3%
LDP (n=31)
7%
Greater than or Equal to 5
Letter Loss
Percent of Subjects (%)
Percent of Subjects With Improvement or Loss From
Baseline in Mesopic BCDVA at 1 Hour
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
9%
23%
27%
39%
Greater than or Equal to 5
Letter Gain
Placebo (n=43)
84%
72%
73%
55%
Within 5 Letters
No Loss of Distance
Vision
Source: VEGA-1 TLR Table 14.2.8.1 and 14.2.10.1 Percent of Subjects With Improvement or Loss From Baseline in Photopic and Mesopic BCDVA by Time Point (PP)
Nyxol+LDP (n=43) Nyxol (n=30)
7%
5%
0%
7%
Greater than or Equal to 5
Letter Loss
LDP (n=31)
Ocuphire
PHARMAView entire presentation